In this article, we report two young patients who were investigated for recurrent joint pain due to CPPD disease.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Calcium pyrophosphate deposition disease (CPDD) is a type of arthritis caused by the deposition of calcium pyrophosphate crystals, and may present as either acute or chronic arthritis.
📊
Key Findings & Data:Development of CPPD crystal deposition disease in young people may be associated with metabolic diseases such as hemochromatosis, hyperparathyroidism, hypomagnesemia, Wilson's disease, hypothyroidism, gout, acromegaly, and X-linked hypophosphatemic rickets.
💡
Conclusion & Impact:In this article, we report two young patients who were investigated for recurrent joint pain due to CPPD disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Calcium pyrophosphate deposition disease (CPDD) is a type of arthritis caused by the deposition of calcium pyrophosphate crystals, and may present as either acute or chronic arthritis. Development of CPPD crystal deposition disease in young people may be associated with metabolic diseases such as hemochromatosis, hyperparathyroidism, hypomagnesemia, Wilson's disease, hypothyroidism, gout, acromegaly, and X-linked hypophosphatemic rickets. Therefore, investigations for a predisposing metabolic condition are advised in young-onset polyarticular CPPD crystal deposition disease. In this article, we report two young patients who were investigated for recurrent joint pain due to CPPD disease.
🔖
Cite This Article
WICKREMATILAKE, G. (2017). Calcium Pyrophosphate Dihydrate Deposition Disease in Young Patients: Two Case Reports. art, Cilt: 32 - Sayı: 1, 80–83. https://ajindex.com/articles/165048
Ahn JK, Kim HJ, Kim EH, Jeon CH, Cha HS, Ha CW, et al. Idiopathic calcium pyrophosphate dihydrate (CPPD) crystal deposition disease in a young male patient: a case report. J Korean Med Sci 2003;18:917-20
Hughes AE, McGibbon D, Woodward E, Dixey J, Doherty M. Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995;4:1225-8
Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009;48:711-5
Netter P, Bardin T, Bianchi A, Richette P, Loeuille D. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine 2004;71:365-8. 6. van der Korst JK, Geerards J, Driessens FC. A hereditary type of idiopathic articular chondrocalcinosis. Survey of a pedigree. Am J Med 1974;56:307-14
Al-Tubaikh JA. CPPD and HADD. Internal Medi cine. An Illustrated Radiological Guide. Chapter 47. Berlin Heidelberg; Springer-Verlag; 2010. p. 265-8
Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70:563-70
Abhishek A, Doherty M. Pathophysiology of articular chondrocalcinosis--role of ANKH. Nat Rev Rheumatol 2011;7:96-104
Doherty M, Dieppe P. Clinical aspects of calcium pyrophosphate dihydrate crystal deposition. Rheum Dis Clin North Am 1988;14:395-414
Longo D, Fauci A, Kasper D. Gout and other crystalassociated arthropathies. Harrison's Principles of Internal Medicine. Chapter 333. 18th ed. New York: McGraw Hill Medical; 2012. p. 2839-40
Perera C, Brook A, Tynns K. Gout and other crystal arthropathies - Part 2. Australian Doctor 2009;21-9
Macmullan P, McCarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis 2012;4:121-31
Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol 2009;21:124-31
Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011;70:571-5
Ea HK, Lioté F. Calcium pyrophosphate dihydrate and basic calcium phosphate crystal-induced arthropathies: update on pathogenesis, cl